Drug Prior Authorization Committee Meeting Information

2022

December DPAC Meeting Minutes
Agenda
Edit Implementation Schedule
PDL Recommendations
PDL Announcements DPAC 2023
New Drugs Edits With No Annual Changes
Dec DPA 2022 - Jan DUR 2023 Reports
PA DUR Slides December 2022

Clinical Edit Proposals - No New Criteria:
Aduhelm Clinical Edit
Antipsychotics, 1st Generation (Typical) Clinical Edit
Benzodiazepine, Select Oral Clinical Edit
Butalbital Combinations without Codeine Clinical Edit
Corlanor Clinical Edit
Empaveli Clinical Edit
HBV Nucleotide Analog Reverse Transcriptase Inhibitors Fiscal Edit
High Risk Therapies Clinical Edit
Kerendia Clinical Edit
Morphine Milligram Equivalent (MME) Accumulation Clinical Edit
Non-Oral Contraceptives Fiscal Edit
Oxazolidinone Fiscal Edit
Pompe Disease Clinical Edit
Selzentry Clinical Edit
Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit
Verquvo Clinical Edit

Clinical Edit Proposals - New Criteria or Revision of Existing Criteria:
Camzyos Clinical Edit
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit
Opioids Short Acting Clinical Edit
Skysona Clinical Edit
Xenpozyme Clinical Edit
Ztalmy Clinical Edit
Zynteglo Clinical Edit

Resource List Edit Review - New Criteria or Revision of Existing Criteria:
Antipsychotics - 2nd Generation (Atypical) Depot Agents
Antipsychotics - 2nd Generation (Atypical) Oral & Transdermal Agents

Preferred Drug List Edit Review - Existing Criteria:
Alzheimer’s Agents, AChEIs and NMDA Receptor Antagonists & Combinations PDL Edit
Antiemetics, 5-HT3 and NK1 Injectables PDL Edit
Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables PDL Edit
Anti-Migraine, Serotonin (5-HT1) Receptor Agonists PDL Edit
Anti-Parkinsonism, MAO-B Inhibitors PDL Edit
Anti-Parkinsonism, Non-Ergot Dopamine Agonists PDL Edit
Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors PDL Edit
Glucagon Agents PDL Edit
Hereditary Angioedema Agents PDL Edit
NSAIDs PDL Edit
Opioid Emergency Reversal Agents PDL Edit
Opioids, Long Acting PDL Edit
Somatostatin Analogs PDL Edit
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors PDL Edit

Preferred Drug List Edit Review - New Criteria or Revision of Existing Criteria:
Antiandrogenic Agents PDL Edit
Anticonvulsants, Dravet Syndrome PDL
Anti-Migraine, Alternative Oral Agents PDL Edit
Antiplatelet Agents PDL Edit
Antiretroviral Therapy (ART) PDL Edit
Calcitonin Gene-Related Peptide (CGRP) Inhibitors PDL Edit
Fibromyalgia Agents PDL Edit
GI Motility Agents, Chronic PDL Edit
Mitogen-activated Extracellular Kinase Inhibitors (MEKi) & B-raf Kinase Inhibitors (BRAFi) PDL Edit
Neuropathic Pain Agents PDL Edit
Opioid & Select Alcohol Dependence Agents PDL Edit
Sedative Hypnotics PDL Edit
Skeletal Muscle Relaxants PDL Edit
Tramadol-Like Agents PDL Edit

September DPAC Minutes

Agenda
Edit Implementation Schedule
PDL Announcement
PDL Recommendations
New Drugs and Edits with No Annual Changes
September DPAC Reports

Clinical Edit Proposals - No New Criteria:
Entresto
Spinal Muscular Atrophy (SMA)

Clinical Edit Proposals -New Revised Criteria:
Alpelisib
ATTR

PDL Proposals - No New Criteria:
ACEI_ACEI-Diuretic Combinations
ACEI_CCB Combinations
ADHD, Methylphenidate SA
ADHD, Non-Stimulants
Alpha Glucosidase Inhibitors
Amylin Analogs
Antibiotics, Mupirocin Topical
Antihyperuricemic Agents
ARB_ARB-Diuretic Combos
ARB-CCB Combos
BB_BB-Diuretic Combos
Benign Prostatic Hyperplasia (BPH) Agents
Biguanides and Combination Agents
Bone Ossification Agents
CCB, Non-DHP
Cephalosporins
Direct Renin Inhibitors and Combos
DPPIV Inhibitors
Electrolyte Depleting Agents, Phosphate Lowering
Erythropoiesis Stimulating Agents
Fluoroquinolones, Oral
Homozygous Familial Hypercholesterolemia (HoFH)
Insulin, Mixed
Insulin, Non-Analogs
Insulin, Rapid Acting
Macrolides
Meglitinides
Methotrexate Agents
Niacin Derivatives
PAH, ETRAs
PAH, PDE5-SGC
PAH, Prostacyclins Oral
Penicillins
SGLT2 Inhibitors_PDL Proposal_9.15.22
Statins and Combos
Sulfonylurea Agents, Second Generation
Tetracyclines
Thiazolidinediones and Combinations
Thrombocytopenia Agents
Triglyceride Lowering Agents

PDL Proposals - New Revised Criteria:
ADHD, Amphetamines long active
ADHD, Amphetamines Short Acting
ADHD, Methylphenidate long acting
Antibiotics, GI Oral
Antibiotics, Vaginal
Anticoagulants, Oral and Subcutaneous
Anticonvulsants, Rescue Agents
Antiplatelet Agents
Bile Salt Agents
CCB, DHP
Colony Stimulating Factors
Cryopyrin-Associated Periodic Syndrome (CAPS)
Dry Eye Disease Agents
Electrolyte Depleting Agents, Potassium Lowering
GLP-1 Receptor Agonists and Combination Agents
Growth Hormone Agents, Somatropin
Growth Hormone and Growth Hormone Releasing Factors, Select Agents
Insulin, Long Acting
LHRH, GnRH Agents, Non-Oral
LHRH, GnRH Agents, Oral
Multiple Sclerosis Agents, Injectable
Multiple Sclerosis Agents, Oral
PAH, Prostacyclins Inhaled
PAH, Prostacyclins Injectable
PCSK9 Inhibitors
Proton Pump Inhibitors (PPIs)
Sympatholytics
Targeted Immune Modulators JAK Inhibitors
Targeted Immune Modulators, IL6 Receptor Inhibitor
Targeted Immune Modulators, IL17 Receptor Antagonists
Targeted Immune Modulators, IL23-12 Inhibitors
Targeted Immune Modulators, Misc Allergy and Asthma Related Monoclonal Antibodies
Targeted Immune Modulators, Select Agents
Targeted Immune Modulators, TNF Inhibitors
Urinary Tract Antispasmodics

Approved Minutes
Agenda
Edit Implementation Schedule
PDL Announcements
PDL Recommendations
New Drugs & Edits with No Annual Changes Presentation
March DPAC Reports
Asthma Policy Update

Clinical Edit Proposals – No New Criteria:
Imcivree
Megestrol Acetate
Nulibry
Oxervate
Oxlumo
Spravato
Zokinvy
Zulresso

Clinical Edit Proposals – New Revised Criteria:
Acne or Rosacea - Select Topical Agents
C5 Complement Inhibitors
CFTR Modulators
Fabry Disease
Givlaari
Isturisa
Scenesse
Sickle Cell Disease
Systemic Antifungals
Tavneos
Voxzogo

PDL Proposals – No New Criteria:
Actinic Keratosis Agents, Topical
Androgenic Agents
Antibiotics, Inhaled
Antifungals, Oral
Antifungals, Topical
Antihistamines and Antihistamine-Decongestant Combinations, Second Generation
Antihistamines, Intranasal
Antivirals, Herpes Oral
Antivirals, Topical
Benzoyl Peroxide-Antibiotic Combinations
Corticosteriods, Oral Inhaled
Corticosteroids and Rhinitis Agents, Intranasal
Corticosteroids, Topical
Cough-Cold Preparation
Epinephrine Agents, Self-Injectable
Fluoroquinolones, Ophthalmic
Fluoroquinolones, Otic
Glaucoma Agents
Mast Cell Stabilizers, Ophthalmic
NSAIDS, Ophthalmic
Psoriasis Agents, Oral
Psoriasis Agents, Topical
Retinoids, Topical
Ulcerative Colitis Agents, Oral
Ulcerative Colitis Agents, Rectal

PDL Proposals – New Revised Criteria:
Anticholinergics LABAs-ICS Combinations and PDE4 Inhibitors
Anticholinergics, Long Acting Beta Adrenergics Combinations
Anticholinergics, Long Acting Inhaled
Anticholinergics, Short Acting and Combinations Inhaled
Antihistamines, Ophthalmic
Antiparasitics, Topical
Atopic Dermatitis Agents, Immunomodulators
Beta Adrenergic Agents, Short Acting
Beta Adrenergic Agents, Long Acting
Beta Adrenergic Agents, Nebulized
Corticosteroids, Ophthalmic Soft
Hepatitis C Agents
Leukotriene Receptor Modifiers
Pancreatic Enzymes
Respiratory Monoclonal Antibodies

2021

Draft Minutes
Agenda
Edit Implementation Schedule
PDL Recommendations
PDL Announcements
New Drugs & Edits with No Annual Changes Presentation
December 2021 – January 2022 DPAC Reports

Opioid Policy Review Edits:
High Risk Therapies
MHD Opioid Policy Update
MME
Opioid Dependence Agents
Opioid Emergency Reversal Agents
Opioids - Long Acting
Opioid - Short Acting
TIRF
Tramadol-Like Agents

Clinical Edit Proposals – No New Criteria:
15 Day Supply Oral Oncology
Butalbital Combo without Codeine
Butalbital Combo Excessive Therapy
Diabetic Supply Quantity Limitation
Out of State Pharmacies
Selzentry

Clinical Edit Proposals – New Revised Criteria:
15 Day Supply
Antipsychotics, 1st Gen (Typical)
Antipsychotics, 2nd Gen (Atypical)
APAP Accumulation
Benzodiazepines - Select Oral
BiDil
Biosimilar vs Reference Products
Corlanor
Empavel
Extended Supply
High Cost Medications
Kerendia
Non-Oral Contraceptives
Pompe Disease
Spinal Muscular Atrophy (SMA)

PDL Proposals – No New Criteria:
Alzheimer's Agents
Anticonvulsants, Dravet Syndrome
Antiemetics, THC Derivatives
Anti-Parkinsonism, MAO-B Inhibitors
Anti-Parkinsonism, Non-Ergot Dopamine Agonists
GI Motility Agents, Chronic
Sedative Hypnotics
Somatostatin Analogs

PDL Proposals – New Revised Criteria:
Antiandrogenic Agents
Antiemetics, 5-HT3 and NK1 Injectables
Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables
Anti-Migraine, Alternative Oral Agents
Anti-Migraine, Serotonin (5-HT1) Receptor Agonists
Antiretroviral Therapy (ART)
Bile Salt Agents
Calcitonin Gene-Related Peptide (CGRP) Inhibitors
CDK4-6 Inhibitors
Fibromyalgia Agents
Glucagon Agents
Hereditary Angioedema Agents
Homozygous Familial Hypercholesterolemia (HoFH)
Neuropathic Pain Agents
NSAIDs
Skeletal Muscle Relaxants
VMAT2 Inhibitors

Minutes
Agenda
Edit Implementation Schedule
PDL Announcements
PDL Recommendations
MHD Pharmacy Program & Budget Update
New Drugs & Edits With No Annual Changes Presentation

Conduent Reports:
September 2021 DPAC Reports

PDL Proposals – No New Criteria:
Angiotensin Receptor Blocker/Angiotensin Receptor Blocker Combo
Angiotensin Receptor Blocker/Calcium Channel Blocker Combo
Beta Adrenergic Blocker/Beta Adrenergic Blockers/Diuretic Combo
Calcium Channel Blockers, Dihydropyridines
Calcium Channel Blockers, Non-Dihydropyridine
Direct Renin Inhibitors
Dry Eye Disease Agents
Niacin Derivatives
PAH Agents, ETRAs
PAH Agents, Prostacylin Pathway Agonists, Inhaled
PAH Agents, Prostacyclin Pathway Agonists, Oral
Sympatholytic Agents

PDL Proposals – New Revised Criteria:
ACE Inhibitors and ACE Inhibitors/Diuretic Combo
ACE Inhibitor/Calcium Channel Blocker Combinations
ADHD, Amphetamines Long Acting
ADHD, Amphetamines Short Acting
ADHD, Methylphenidate Long Acting
ADHD, Methylphenidate Short Acting
ADHD, Non-Stimulant Agents
Anticoagulant Agents, Oral and Subcutaneous
Anticonvulsants, Rescue Agents
Antiplatelet Agents
Homozygous Familial Hypercholesterolemia Agents
PAH Agents, PDE5 and SGC Stimulators
PAH Agents, Prostacyclin Pathway Agonists, Injectable
PCSK9 Inhibitors
Proton Pump Inhibitors
Statins and Combinations
Triglyceride Lowering Agents

Clinical Edits – No New Criteria:
Emsam
Immunoglobulins
Lambert-Eaton Myasthenic Syndrome
Neuromyelitis Optica Spectrum Disorder
Nuedexta
Oxandrin
Palforzia
Ranexa
Transthyretin-Mediated Amyloidosis
Xcopri

Clinical Edits – New Revised Criteria:
Aduhelm
Botulinum Toxin
Equetro
Narcolepsy Inhibitors
Psychotropic Medications Polypharmacy
Serotonin and Norepinephrine Reuptake Inhibitors
Selective Serotonin Reuptake Inhibitor

Minutes
Agenda
New Drugs
Edit Implementation Schedule
PDL Recommendations
PDL Announcements

Conduent Reports:
June 2021 DPAC Reports
CyberAccess User Statistics

PDL Proposals – No New Criteria
Amylin Analogs
Antibiotic, Vaginal
Bile Sale Agents
Cephalosporin Agents
Electrolyte Depleting Agents, Phosphate Lowering
Electrolyte Depleting Agents, Potassium Lowering
Fluoroquinolone Agents, Oral
Insulin, Mixed
Insulin, Non-Analogs
Penicillin Agents
Sulfonylurea Agents, Second Generation
Targeted Immune Modulators, IL6 Receptor Inhibitors
Thrombocytopenia Agents

PDL Proposals – New Revised Criteria
Alpha Glucosidase Inhibitors
Antibiotics, GI Oral
Antibiotics, Mupirocin Topical
Antihyperuricemic Agents
Benign Prostatic Hyperplasia Agents
Biguanides
Bone Ossification Agents
Colony Stimulating Factors
Cryopyrin-Associated Periodic Syndrome (CAPS)
DPPIV Inhibitor
Erythropoiesis Stimulating Agents
GLP-1 Agonists
Growth Hormone Agents, Somatropin
Growth Hormone, Growth Hormone Releasing Factors, Select Agents
Insulin, Long Acting
Insulin, Rapid Acting
LHRH_GnRH Agents, Non-Oral
Macrolide Agents
Meglitinide Agents
Methotrexate Agents
Multiple Sclerosis Agents, Injectable
Multiple Sclerosis Agents, Oral
SGLT2 Inhibitors
Targeted Immune Modulators, IL17
Targeted Immune Modulators, IL23 IL12 inhibitors
Targeted Immune Modulators, JAK Inhibitors
Targeted Immune Modulators, Select Agents
Targeted Immune Modulators, TNF Inhibitors
Tetracycline Agents
Thiazolidinediones
Urinary Tract Antispasmodics

Clinical Edits – No New Criteria:
Ampyra
Elagolix
Gamifant
Koselugo
Luxturna
Oxervate
Reblozyl
Synagis
Tepezza
Tolvaptan
Zometa

Clinical Edits – New Revised Criteria
CAR-T Cell
Crysvita
DMD
Entresto
Extended Supply
HBV Nucleotide Analog
Imcivree
Iron – Injectable
Nulibry
Oxazolidinone
Palynziq
PTH and Other Agents
Verquvo
Zokinvy

2020

Minutes
Agenda - Webex only. See agenda for call in details.
Edit Implementation Schedule
PDL Recommendations
PDL Announcements

Conduent Reports:
FY21 Top 25 Drugs Quarterly Report
CyberAccess User Statistics
Helpdesk Status Report
Logging Table
New Drug Summary

PDL Proposals - New Revised Criteria:
Anticonvulsants, Dravet Syndrome
Antiemetic 5HT3, NK1 Agents, Injectable
Anti-Migraine Alternative Oral Agents
Anti-Migraine 5HT1 Agents
Anti-Parkinsonisms Non-Ergot Dopamine Agonists
Antiretroviral Reference Products
Calcitonin Gene-Related Peptide (CGRP) Inhibitors
CDK4-6 Inhibitors
Fibromyalgia Agents
GI Motility Agents
Glucagon Agents
Neuropathic Pain
NSAID Agents
Opioid Dependence Agents
Opioids Long Acting
Sedative Hypnotics
Skeletal Muscle Relaxants
Somatostatic Analogs
Tramadol-Like Agents
VMAT2 Inhibitors

PDL Proposals - No New Criteria:
Alzheimer’s Agents
Antiandrogenic Agents
Antiemetic 5HT3, NK1, Other Non-Injectable Agents
Antiemetic THC Derivative Agents
Anti-Parkinsonism, MAO-B Inhibitor Agents
Hereditary Angioedema
Opioid Emergency Reversal Agents

Clinical Edit Proposals - No New Criteria:
15 Day Supply Oral Oncology
APAP Accumulation
BiDil
Butalbital Combo without Codeine
Butalbital Combo Excessive Therapy
Corlanor
Entresto
Selzentry

Clinical Edit Proposals - New Revised Criteria:
15 Day Supply
Antipsychotics, 1st Gen (Typical)
Antipsychotics, 2nd Gen (Atypical)
Benzodiazepines Select Oral
Biosimilar vs Reference
Car T Cell
Diabetic Supply Quantity
DMD
High Cost Medication Kits
High Risk Therapies
Isturisa
MME
NMOSD
Non-Oral Contraceptives
Opioids Combos-Short Acting
Opioids Single Agent-Short Acting
Out of State Pharmacies
PolyPharm
PrEP
SMA
TIRF
Agenda
Edit Implementation Schedule
New Drugs
PDL Announcements
PDL Recommendations

Conduent Reports:
CyberAccess User Statistics
Help Desk Status Report
Logging Table
New Drug Summary
Top 20 Drugs Quarterly Report

Proposed PDL Fiscal Edits:
Alpha-Glucosidase Inhibitors PDL Edit
Amylin Analogs PDL Edit
Antibiotics, Gastrointestinal (GI), Oral Agents PDL Edit
Antibiotics, Vaginal Agents PDL Edit
Antihyperuricemic Agents PDL Edit
Anti-Migraine Agents, Alternative Oral Agents PDL Edit
Bile Salt Agents PDL Edit
Bone Ossification Agents PDL Edit
Benign Prostatic Hyperplasia Agents PDL Edit
Cryopyrin-Associated Periodic Syndrome (CAPS) Agents PDL Edit
Cephalosporins PDL Edit
Colony Stimulating Factors PDL Edit
DPP-IV Inhibitors & Combination Agents PDL Edit
Electrolyte Depleters, Phosphate Lowering Agents PDL Edit
Electrolyte Depleters, Potassium Lowering Agents PDL Edit
Erythropoiesis Stimulating Agents PDL Edit
Fluoroquinolones, Oral PDL Edit
Growth Hormones & Growth Hormone Releasing Factors, Select Agents PDL Edit
Growth Hormones, Somatropin Agents Edit
Glucagon-Like Peptide -1 (GLP-1) Receptor Agonists & Combination Agents PDL Edit
Hepatitis C Agents PDL Edit
Insulins, Long Acting PDL Edit
Insulins, Mixed PDL Edit
Insulins, Non-Analogs PDL Edit
Iron - Injectable Step Therapy Edit
Insulins, Rapid Acting PDL Edit
Macrolides PDL Edit
Meglitinides PDL Edit
Methotrexate Agents PDL Edit
Multiple Sclerosis, Injectable Agents PDL Edit
Multiple Sclerosis, Oral Agents PDL Edit
Penicillins PDL Edit
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors & Combination Agents PDL Edit
Sulfonylureas, 2nd Generation PDL Edit
Tetracyclines PDL Edit
Thiazolidinediones & Combination Agents PDL Edit
Thrombocytopenia Agents PDL Edit
Targeted Immune Modulators, Interleukin-6 (IL-6) Receptor Inhibitors PDL Edit
Targeted Immune Modulators, Interleukin (IL)-17 Antibody/IL17 Receptor Antagonists, IL-23 Inhibitors and IL-23/IL-12 Inhibitors PDL Edit
Targeted Immune Modulators, Janus Kinase (JAK) Inhibitors PDL Edit
Targeted Immune Modulators, Select Agents PDL Edit
Targeted Immune Modulators, Tumor Necrosis Factor (TNF) Inhibitors PDL Edit
Urinary Tract Antispasmodics PDL Edit

Proposed Clinical Fiscal Edits:
Ampyra® Clinical Edit
Crysvita® Clinical Edit
Diacomit® Clinical Edit
Gamifant® Clinical Edit
Iron - Injectable Step Therapy Edit
Koselugo™ Clinical Edit
Luxturna® Clinical Edit
Orilissa® Clinical Edit
Oxervate® Clinical Edit
Palynziq™ Clinical Edit
Parathyroid Hormone and Bone Resorption Suppression Related Agents Clinical Edit
Reblozyl® Clinical Edit
Synagis® Clinical Edit
Tepezza™ Clinical Edit
Tolvaptan Clinical Edit (formerly Jynarque® Clinical Edit)
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors Clinical Edit
Minutes
Acne and Rosacea - Select Topical Agents Step Therapy Edit
Actinic Keratosis Agents - Topical PDL Edit
Androgenic Agents PDL Edit
Antibiotic Agents - Inhaled PDL Edit
Antifungal (Onychomycosis/Candidiasis) Agents - Oral PDL Edit
Antifungal Agents - Topicals PDL Edit
Antihistamines/Decongestant Combinations - Low Sedating (2nd Generation) PDL Edit
Antihistamines - Intranasal PDL Edit
Antihistamines - Ophthalmic PDL Edit
Antiparasitic Agents - Topical PDL Edit
Antivirals - Herpes Oral PDL Edit
Atopic Dermatitis Agents - Immunomodulators PDL Edit
Benzoyl Peroxide - Antibiotic Combinations PDL Edit
Beta Adrenergic Agents - Long Acting PDL Edit
Beta Adrenergic Agents - Nebulized PDL Edit
Beta Adrenergic Agents - Short Acting PDL Edit
Clobazam Agents Clinical Edit
COPD Anticholinergic Agents PDL Edit
Corticosteroids Oral - Inhaled PDL Edit
Corticosteroids and Rhinitis Agents - Intranasal PDL Edit
Corticosteroids - Ophthalmic “Soft” Steroids PDL Edit
Corticosteroids - Topical PDL Edit
Cough and Cold Preparations PDL Edit
Duchenne Muscular Dystrophy (DMD) Clinical Edit
Drug PA Agenda
Drug PA Meeting
Edit Implementation Schedule
Epidiolex® (cannabidiol) Clinical Edit
Epinephrine Self-Injectable Agents PDL Edit
Fluoroquinolones - Ophthalmic PDL Edit
Fluoroquinolones - Otic PDL Edit
Galafold® (migalastat) Clinical Edit
Givlaari™ (givosiran) Clinical Edit
Glaucoma Agents PDL Edit
Leukotriene Modifiers PDL Edit
Mast Cell Stabilizers - Ophthalmic PDL Edit
Megestrol Acetate Clinical Edit
MO Healthnet Pharmacy Program And Budget Update
New Drugs
Nocturnal Polyuria Clinical Edit
Nonsteroidal Anti-Inflammatory Drugs (NSAID) - Ophthalmic PDL Edit
Pancreatic Enzyme Agents PDL Edit
Preferred Drug List Announcement
Psoriasis Agents - Oral PDL Edit
Psoriasis Agents - Topical PDL Edit
Reblozyl® (luspatercept-aamt) Clinical Edit
Retinoids - Topical PDL Edit
Sickle Cell Disease Clinical Edit
Spravato® (esketamine) Clinical Edit
Systemic Antifungals Clinical Edit
Top 25 Drugs Quarterly Reports
Ulcerative Colitis Agents ─ Oral PDL Edit
Ulcerative Colitis Agents ─ Rectal PDL Edit